ArticlePloS one2026
Co-modulation of clinical courses of hypertension and depression in public health facilities in Ethiopia: A six-month follow-up study protocol.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe co-occurrence of hypertension and depression is increasing both in magnitude and complexity, negatively impacting treatment outcomes of both conditions. Given that both conditions are chronic, the impact of each condition over time on the other needs to be well understood. This project aims to examine how each condition affects the course and outcome of the other over a six-month follow-up period.
methodsFour hundred eighty-five adults with newly diagnosed hypertension will be screened for depression using the nine-item Patient Health Questionnaire (PHQ-9) at the time of diagnosis. We will employ a prospective cohort study design, with depression serving as the exposure variable. At baseline, blood pressure, depression level, co-morbid illness, perceived social support, substance use, pain level, health-related quality of life, and disability will be measured. At three and six months, blood pressure, depression level, health-related quality of life, and disability measurements will be repeated. The prevalence of depression will be determined at baseline, and the factors associated with it will be examined using Poisson regression with a robust variance estimator. The incidence of depression will be calculated at 3 months and 6 months. The effect size of the change from baseline to endpoint will be measured using Cohen's d. To identify the predictors of change in PHQ-9 scores over time, multilevel mixed-effects linear regression will be employed. Blood pressure control at three and six months will be evaluated, and the impact of baseline depression on blood pressure control will be analysed. P-values less than 0.05 will be considered statistically significant. ETHICS: The Institutional Review Board of the College of Medicine and Health Sciences, Bahir Dar University, has approved the study. ANTICIPATED IMPACT: The findings will contribute to the scarce body of knowledge about long-term interaction between hypertension and depression, particularly on the impact of unmanaged depression on hypertension control, and the incidence of depression in hypertension patients. Findings on the course of depression will help clinicians to decide on the dilemma of treating it or expecting spontaneous recovery with the effective management of hypertension.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.